Precision Nutrition Testing is the Future of Personalized Care: Evidence and Coverage Policies for Equitable Access

Clicks: 13
ID: 327891
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #121 of 168 articles by views in Health Affairs Scholar

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 168 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract The one-size-fits-all approach to dietary and metabolic interventions often fails to improve population health outcomes. This problem has been made more urgent by the rise of GLP-1 receptor agonist medications for obesity, which are high-cost but have variable patient outcomes. Precision nutrition (PN) testing has the potential to address this gap by using biomarkers, such as genetics and metabolic profiles, to predict individual responses to foods and drug therapies. Although some PN tests are on the market, most are not FDA-approved or covered by insurers, requiring out-of-pocket payment and creating access disparities. In this Commentary, we draw on experience from precision medicine to argue that payers, developers, regulators, and professional societies must begin building the evidence and coverage infrastructure for PN testing now. Payer coverage will require demonstrated clinical utility and defined clinical pathways that guide who should be tested and how results should change care. The policy question is not whether current tests should be covered; they should not be broadly covered without evidence, but whether the health system is preparing for equitable implementation once validated tests emerge. Building evidence and coverage infrastructure proactively will help ensure that future PN testing innovations improve population health equitably rather than widen existing disparities.
Reference Key
openalex_W7211906340 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Danea Horn, Hilary K. Seligman, Kathryn A. Phillips
Are you one of these authors? Claim your profile
Journal Health Affairs Scholar
Year 2026
DOI
10.1093/haschl/qxag247
URL
https://doi.org/10.1093/haschl/qxag247
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.